Profil
Lynn Gallant worked as Vice President-Clinical Operations at BlueRock Therapeutics Canada ULC and Enveric Biosciences, Inc. Ms. Gallant obtained an undergraduate degree from the University of New England.
Ehemalige bekannte Positionen von Lynn Gallant
| Unternehmen | Position | Ende |
|---|---|---|
| ENVERIC BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2023 |
BlueRock Therapeutics Canada ULC
 BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Lynn Gallant
| University of New England | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ENVERIC BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
BlueRock Therapeutics Canada ULC
BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Health Technology |
